Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vipul Brahmbhatt

Clinical Cardiac Electrophysiology Johnson City, TN Medical Doctor

NPI 1679559165 CMS profile 609821

310 N State Of Franklin Rd Ste 400, Johnson City, TN 37604

Open in the dashboard

General payments

$14,503

341 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,200 paid to institutions, not to them · program year 2019

Through program year 2025, Vipul Brahmbhatt of Johnson City, TN is reported in the CMS Open Payments database as having received $14,503 across 341 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,200 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 43rd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,044 31
2024 General $379 21
2023 General $2,680 74
2022 General $4,183 46
2021 General $818 48
2020 General $775 47
2019 General $4,624 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vipul Brahmbhatt
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Vipul Brahmbhatt were reported at $1,044. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Vipul Brahmbhatt Clinical Cardiac Electrophysiology median Middle half National median
2019 $4,624 $2,361 $585–$8,260 $163
2020 $775 $993 $247–$4,351 $114
2021 $818 $1,185 $326–$4,739 $132
2022 $4,183 $2,073 $554–$6,789 $149
2023 $2,680 $2,568 $759–$8,159 $160
2024 $379 $2,557 $703–$7,403 $164
2025 $1,044 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $3,767 42 payments
  2. Medtronic, Inc. $3,297 26 payments
  3. Abbott Laboratories $3,043 35 payments
  4. Boston Scientific Corporation $745 29 payments
  5. Novartis Pharmaceuticals Corporation $734 51 payments
  6. AstraZeneca Pharmaceuticals LP $644 47 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $443 43 payments
  8. Atricure, Inc. $358 7 payments
  9. Respicardia, Inc. $163 1 payment
  10. Aziyo Biologics, Inc. $158 9 payments
  11. Other $1,150 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $7,976 18 payments
  2. Food and Beverage $6,403 320 payments
  3. Education $125 3 payments
Products named General payments · program years 2019–2025
  1. AVEIR $2,014 9 payments
  2. MICRA $1,444 14 payments
  3. ENSITE $634 3 payments
  4. EVERA MRI XT DR SURESCAN $542 2 payments
  5. LifeVest $443 43 payments
  6. ENTRESTO Cardiovascular $333 24 payments
  7. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $319 6 payments
  8. BRILINTA $319 25 payments
  9. FARXIGA $303 21 payments
  10. ENTRESTO Cardiology/Vascular Diseases $245 18 payments
  11. Other $3,866 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

5,188

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,022,426

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

41.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 571 $507,163
Xarelto Rivaroxaban Brand 201 $180,715
Entresto Sacubitril/Valsartan Brand 122 $121,172
Farxiga Dapagliflozin Propanediol Brand 79 $65,014
Jardiance Empagliflozin Brand 24 $24,979
Dofetilide Generic 109 $18,007
Multaq Dronedarone Hcl Brand 11 $16,359
Flecainide Acetate Generic 439 $15,507
Brilinta Ticagrelor Brand 14 $12,413
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 13 $6,385

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$327,887

Of which drugs: $2,040

Medicare patients

1,042

Average age 75

Services billed

3,676

571 women, 471 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 56%
Ischemic heart disease 53%
Arthritis 48%
Chronic kidney disease 41%
Diabetes 39%
Heart failure 39%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 61 244 $1,230
Injection, sulfur hexafluoride lipid microspheres, per ml Q9950 Office 11 55 $810

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $31
$31 122 —
Repatha
  • Amgen Inc. $16
$16 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $15
$15 201 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $15
$15 79 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

341 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record